Pfizer Inc (PFE.N), beating out numerous other bidders, said it would buy U.S. cancer drug company Medivation Inc (MDVN.O) for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.
Medivation shares were up 20 percent at $80.43 in midday trading, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were little changed.
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff13
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle14
03:00 Carrier incentives stir debate over 'rewarding' offshoring13
01:02 A company Trump attacked will receive state tax breaks to keep jobs in the U.S13